Insulin degludec biosimilar - Amphastar Pharmaceuticals
Alternative Names: AMP 025Latest Information Update: 26 Mar 2024
At a glance
- Originator Amphastar Pharmaceuticals
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Diabetes mellitus